界面新闻记者 |陈杨界面新闻编辑 |谢欣3月30日晚间,国内创新药公司康方生物发布2024年业绩。当期,公司营收21.40亿元,同比下滑53.08%;年度亏损5.01亿元,重新转亏。3月31日开盘,康方生物股价高冲,但随后回落。收盘价报76.200港元/股,涨2.14%,当下市值683.95亿港元。实际上,前述业绩变化源于康方生物2023年有主要来自合作方Summit的大额商业授权收入。到2024...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.